Revenue of leading public RNA-based biotech companies worldwide 2023
In 2020, Moderna reported around 803 million U.S. dollars of revenue, but two years after that the company made more than 19 billion U.S. dollars, mostly through its very successful COVID-19 vaccine named Spikevax. This statistic illustrates revenues of leading public RNA-based biotech companies worldwide in 2020, 2022, and 2023.
